TY - JOUR
KW - buprenorphine
KW - HIV
KW - Extended-release naltrexone
KW - Methadone
KW - non-inferiority trial
KW - opioid-related disorders
KW - Randomized Controlled Trials
AU - P. T. Korthuis
AU - R. R. Cook
AU - P. J. Lum
AU - E. N. Waddell
AU - H. Tookes
AU - P. Vergara-Rodriguez
AU - L. E. Kunkel
AU - G. M. Lucas
AU - A. E. Rodriguez
AU - S. Bielavitz
AU - L. C. Fanucchi
AU - K. A. Hoffman
AU - K. Bachrach
AU - E. H. Payne
AU - J. A. Collins
AU - A. Matthews
AU - N. Oden
AU - P. Jacobs
AU - E. Jelstrom
AU - J. L. Sorensen
AU - D. McCarty
A1 - 
AD - Addiction Medicine Program, Oregon Health and Science University, Portland, OR, USA.; Oregon Health and Science University-Portland State University School of Public Health, Portland, OR, USA.; Addiction Medicine Program, Oregon Health and Science University, Portland, OR, USA.; Division of HIV, ID and Global Medicine, University of California, San Francisco, CA, USA.; Addiction Medicine Program, Oregon Health and Science University, Portland, OR, USA.; Oregon Health and Science University-Portland State University School of Public Health, Portland, OR, USA.; Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA.; Ruth M. Rothstein CORE Center, Department of Psychiatry and Department of Internal Medicine, Cook County Health, Chicago, IL, USA.; Addiction Medicine Program, Oregon Health and Science University, Portland, OR, USA.; Johns Hopkins School of Medicine, Baltimore, MD, USA.; Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA.; Addiction Medicine Program, Oregon Health and Science University, Portland, OR, USA.; Division of Infectious Diseases and Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, USA.; Oregon Health and Science University-Portland State University School of Public Health, Portland, OR, USA.; Tarzana Treatment Centers, Tarzana, CA, USA.; Emmes Company, LLC, Rockville, MD, USA.; Emmes Company, LLC, Rockville, MD, USA.; Emmes Company, LLC, Rockville, MD, USA.; Emmes Company, LLC, Rockville, MD, USA.; National Institutes of Health, National Institute on Aging, Bethesda, MD, USA.; Emmes Company, LLC, Rockville, MD, USA.; Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA.; Addiction Medicine Program, Oregon Health and Science University, Portland, OR, USA.; Oregon Health and Science University-Portland State University School of Public Health, Portland, OR, USA.
BT - Addiction (Abingdon, England)
C5 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
CY - England
DO - 10.1111/add.15836
JF - Addiction (Abingdon, England)
LA - eng
M1 - Journal Article
PB - The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction
PP - England
PY - 2022
SN - 1360-0443; 0965-2140
T1 - HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial
T2 - Addiction (Abingdon, England)
TI - HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial
U1 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
U2 - 35129242
U3 - 10.1111/add.15836
VO - 1360-0443; 0965-2140
Y1 - 2022
Y2 - Feb 7
ER -